Posted: June 27, 2025
See what we unveiled at ISTH 2025! VIEW VIDEO We are grateful for the opportunity to connect and discuss the latest advancements for the hemostasis laboratory at ISTH 2025. The science and collaboration were outstanding. Many thanks to all who worked so hard to make it a success! DiaPharma was proud to highlight: CLINICAL &…
Posted: June 23, 2025
Contributed by Abigail Kasberg, PhD Alcohol-related clinical trials play a fundamental role in advancing our understanding of the complex impact of alcohol consumption on human health. The prevalence of alcohol use is widespread, causing a systemic impact on the individual and affecting whole communities. Clinical trials are a means to investigate the mechanisms of alcohol-related…
Posted: April 11, 2025
David L. McGlasson, MS, MLS(ASCP) A recent episode of “Differential Discussions” digs into the utility of the chromogenic factor X (CFX) assay for monitoring patients on oral anticoagulant therapy (OAT). Data from previous studies and a case study were discussed. A study was presented that compared International Normalized Ratio (INR) values with CFX results, to…
Posted: March 31, 2025
— Contributed by Olivia Stricker, PhD and Jessica Tuohy, PhD The 2025 AASLD Emerging Topics Conference in Las Vegas delivered an invigorating discussion on one of the most pressing challenges in hepatology today—metabolic dysfunction-associated alcohol-related liver disease (metALD) and the evolving landscape of ALD clinical trials. As research advances, our understanding of these diseases continues…
Posted: December 10, 2024
-Contributed by Abi Kasberg, PhD Immunothrombosis defines the delicate intersection of innate immunity and coagulation. This complex bidirectional interaction between the immune system and clotting components activate each other, leading to abnormal clotting events when unbalanced. A central component to immunothrombosis is the NETosis response of activated neutrophils that result in the expulsion of neutrophil…
Posted: December 10, 2024
-Contributed by Olivia Stricker, PhD and Abi Kasberg, PhD The relationship between metabolic disorders and liver disease is striking. Liver disease affects 75% of individuals with type 2 diabetes (T2D), making metabolic disorders the most common underlying cause of liver disease in the U.S (Gobejishvili et al. 2024). The liver diseases associated with T2D range…
Posted: November 13, 2024
David McGlasson The complexities of testing for hemophilia A and B are vast. This Clot Club post serves as an overview of what the laboratory must consider when testing for new EHL products. When comparing different methods used to determine FVIII and FIX activity, the testing laboratory should evaluate the calibrators used, individual kit…
Posted: September 12, 2024
It’s Not Just Support. It’s Solutions. VISIT DIAPHARMA AT THESE UPCOMING EVENTS! Connect with DiaPharma to discuss all the latest in hemostasis and liver disease. Interested in learning more about the cytokeratin 18 (CK18) biomarker assays, M30® Apoptosense and M65 ELISA®, for MASH, ALD/AH, DILI , or any of our other cutting edge products? Make…
Posted: September 11, 2024
It’s Not Just Support. It’s Solutions. VISIT DIAPHARMA AT THESE UPCOMING EVENTS! Connect with DiaPharma to discuss all the latest in hemostasis and liver disease. Interested in learning more about the Ceveron s100*, the FDA-cleared T-TAS 01, Technozym ADAMTS13 Activity ELISA for IVD use, M30® Apoptosense ELISA for liver damage, or any of our other…